A5207- Maintaining Options for Mothers Study (MOMS) – A Phase II Randomized Comparison of three Antiretroviral Strategies administered for 7 or 21 days to reduce the emergence of Nevirapine resistant HIV-1 following a single Intrapartum dose of Nevirapine